NCT02501421View on ClinicalTrials.gov

Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

February 28, 2015

Conditions
Tuberculosis
Interventions
BIOLOGICAL

tuberculosis vaccine

Live recombinant influenza vectored tuberculosis vaccine

BIOLOGICAL

Placebo

Buffer

All Listed Sponsors
collaborator

Ministry of Health, Kazakhstan

OTHER_GOV

collaborator

Research Institute of Influenza, Russia

OTHER

lead

Research Institute for Biological Safety Problems

OTHER_GOV

NCT02501421 - Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine | Biotech Hunter | Biotech Hunter